Literature DB >> 8324614

Contraceptive delivery in the developing world.

D M Potts1, S F Crane.   

Abstract

A strong demand for family planning exists in most developing countries and family size is falling rapidly in many of them. Effective family planning programmes offer a world-wide range of choices (including voluntary sterilisation and abortion) through a variety of distribution channels. Universal access to voluntary family planning can be achieved easily and cheaply by the turn of the century, but only if conservative medical policies are overcome and funding is greatly expanded. The international community faces a genuine choice: if it responds to current opportunities the global population will stabilize at approximately 10 billion or fewer; if it fails, population may grow to 14 billion or more. The difference between these two projections (approximately equal to the present world population of 5.4 billion) may well determine the future of the planet.

Entities:  

Keywords:  Birth Rate; Contraception; Contraceptive Distribution; Contraceptive Implants--cost; Contraceptive Methods; Contraceptive Methods--cost; Couple Years Of Protection; Critique; Demographic Factors; Developing Countries; Diseases; Distributional Activities; Family Planning; Family Planning Program Evaluation; Family Planning Programs; Fertility; Fertility Decline; Fertility Measurements; Fertility Rate; Hiv Infections; Infections; Iud; Oral Contraceptives; Organization And Administration; Population; Population Dynamics; Program Activities; Programs; Reproductive Tract Infections; Sexually Transmitted Diseases; Sterilization, Sexual; Total Fertility Rate--changes; Viral Diseases; World

Mesh:

Year:  1993        PMID: 8324614     DOI: 10.1093/oxfordjournals.bmb.a072604

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  2 in total

1.  Natural family planning. ...and empowers couples.

Authors:  G Jarvis
Journal:  BMJ       Date:  1993-11-20

Review 2.  Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

Authors:  James Drife
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.